All In MedTech

Device Trial Radar · NCT05650866

Safety and Tolerability of a Novel Implantable Device for the Treatment of Erectile Dysfunction

Safety and Tolerability of a Novel Implantable Device for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

May 19, 2023

Primary completion

Jun 30, 2028

Study completion Jun 30, 2028

Sponsor

Lead sponsor
Comphya AustraliaNot on our public-company list
Sponsor type
Industry
First posted
Dec 14, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
Male only, from 30 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to assess if a new device is safe to use as a potential treatment for erectile dysfunction following radical prostatectomy. The main questions it aims to answer are: * Is the device safe? * Does the device works well? Are the participants satisfied with the device? Participants will be implanted with the device during the ongoing prostatectomy surgery and will be asked to complete the following tasks during 6 months follow-up: * Come to the hospital for follow-up visits, * Complete questionnaires, * Activate the device every day, * Measure erection hardness. Researchers will compare an implanted group (participants having the device) with a control group (participants not having the device) to see if the device works well.

Conditions

  • Erectile Dysfunction Following Radical Prostatectomy

Interventions

  • Activation of pro-erectile nerves within the pelvic plexusDevice

    The study device is an active implantable device. The device activates the cavernous nerves by delivering electrical pulses, to trigger an on-demand erection. The daily delivery of electrical pulses to the cavernous nerves will also allow participants to recover natural erectile function.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of adverse eventsTime frame: 6 months
  2. Occurrence of surgical complicationsTime frame: 6 months
  3. Occurrence of device deficienciesTime frame: 6 months

1 more outcomes with a free account

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • St. Vincent's Private Hospital

    Fitzroy, Victoria, Australia

  • Royal Melbourne Hospital

    Melbourne, Victoria, Australia

  • Australian Prostate Centre

    North Melbourne, Victoria, Australia

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.